Corvus Pharmaceuticals' stock plummeted ~40% after Phase 1 data for soquelitinib in AD showed mixed results. See why I ...

Corvus Pharmaceuticals develops next-gen ITK inhibitors, with promising Phase 1 results. Read why CRVS stock can thrive in ...

Corvus Robotics, a provider of autonomous inventory management systems, today announced that it has recruited Rob Stevens, ...

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from ...

Corvus Robotics' autonomous drones are revolutionizing warehouse inventory management with precision and efficiency.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients ...

Nukkleus Inc. NUKK gained 55.1% to $18.42 in pre-market trading. Nukkleus shares jumped 755% on Tuesday after the company ...

Mizuho views the selloff yesterday in shares of Corvus Pharmaceuticals (CRVS) following the Phase 1 data for soquelitinib in atopic dermatitis ...

Investing.com -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS)股票最初下跌高达18%，但随后出现显著反转，在公布其用于治疗中度至重度特应性皮炎的soquelitinib的I期试验中期结果后上涨7%。这家临床阶段生物制药公司发布的数据显示了良好的安全性和有效性，表明该药物不仅对这种慢性皮肤病有潜力，对其他免疫疾病也有潜力。

Corvus Energy has been selected as the supplier of Energy Storage Systems (ESS) for Statue City Cruises’ ferries servicing ...

Corvus Pharmaceuticals (CRVS) announced interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating ...

The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara ...